First Header Logo Second Header Logo

Connection

Ravi Paluri to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Ravi Paluri has written about Dose-Response Relationship, Drug.
Ravi Paluri
Connection Strength
0.148
Dose-Response Relationship, Drug
  1. Paluri R, Madan A, Li P, Jones B, Saleh M, Jerome M, Miley D, Keef J, Robert F. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2019 03; 83(3):551-559.
    View in: PubMed
    Score: 0.148
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.